RA Capital logo

RA Capital

Crunchbase
Pitchbook
Crunchbase

Deals on record

28

Common Fundraising Type

Series A

Be Bio logo
Be Bio

Engineered B Cell Medicines

Nextech logo
Takeda Ventures logo
RA Capital Management logo
Longwood Fund logo
Bristol Myers Squibb logo
Atlas Venture logo
Arch Venture Partners logo
Alta Partners logo

Be Biopharma is developing engineered B cell medicines to produce therapeutic proteins for treating conditions like Hemophilia B and Hypophosphatasia.

Series C
$92M
01/15/2025
Article
Verdiva Bio logo
Verdiva Bio

Biopharmaceutical

General Atlantic logo
Forbion logo
RA Capital Management logo
OrbiMed logo
Logos Capital logo
Lilly Asia Ventures logo
LYFE Capital logo

Verdiva Bio is a clinical-stage biopharmaceutical company developing next-generation oral and injectable treatments for obesity and cardiometabolic disorders.

Series A
$411M
01/09/2025
Article

Indapta Therapeutics develops allogeneic Natural Killer (NK) cell therapies for treating cancer and autoimmune diseases.

Equity
$22.5M
12/17/2024
Article
Adcendo logo
Adcendo

Biotech

TCGX logo
Ysios Capital logo
Venrock Healthcare Capital Partners logo
Surveyor Capital logo
RA Capital Management logo
Pontifax Venture Capital logo
Novo Holdings logo
Logos Capital logo

Adcendo is a biotech company focused on developing antibody-drug conjugates for treating cancers with high unmet needs.

Series B
$135M
11/25/2024
Article
Synapticure logo
Synapticure

Virtual care

B Capital logo
CommonSpirit Health logo
CVS Health Ventures logo
Google Ventures logo
Optum Ventures logo
Rock Health Capital logo
RA Capital Management logo
Nexus NeuroTech Ventures logo

Synapticure is a virtual care company that provides comprehensive care for neurodegenerative diseases like Alzheimer's, Parkinson's, and ALS across the United States.

Series A
$25M
11/19/2024
Article
Metsera logo
Metsera

Biopharmaceutical

Venrock logo
Wellington Management logo
T. Rowe Price logo
SymBiosis logo
SoftBank logo
Newpath Partners logo
Janus Henderson logo
GV logo

Metsera is a clinical-stage biopharmaceutical company developing next-generation treatments for obesity and metabolic diseases using their innovative platforms and Nutrient-Stimulated Hormone analog peptides.

Series B
$215M
11/13/2024
Article
Trace Neuroscience logo
Trace Neuroscience

Genomic therapies

Third Rock Ventures logo
GV logo
RA Capital Management logo
Atlas Venture logo

Trace Neuroscience is a biopharmaceutical company developing genomic therapies for neurodegenerative diseases, with a focus on treating amyotrophic lateral sclerosis (ALS) by restoring the UNC13A protein.

Series A
$101M
11/12/2024
Article

Alentis Therapeutics is a biotech company developing antibody-drug conjugates for treating Claudin-1 positive tumors and organ fibrosis.

Series D
$181.4M
11/12/2024
Article
Evommune logo
Evommune

Biotechnology

RA Capital Management logo
Verition Fund Management logo
Symbiosis logo
RTW Investments logo
Sectoral Asset Management logo
Pivotal bioVenture Partners logo
NEXTBio Capital logo
Marshall Wace logo

Evommune, Inc. is a biotechnology company focused on developing treatments for chronic inflammatory diseases.

Series C
$115M
10/31/2024
Article
Alpha-9 Oncology logo
Alpha-9 Oncology

Radiopharmaceuticals

Ascenta Capital logo
Lightspeed Venture Partners logo
Samsara BioCapital logo
RA Capital Management logo
Nextech Invest logo
Longitude Capital logo
General Catalyst logo
Digitalis Ventures logo

Alpha-9 Oncology Inc. develops targeted radiopharmaceuticals to improve cancer treatment.

Series C
$175M
10/23/2024
Article
Be Bio logo
Be Bio

Engineered B Cell Medicines

Takeda Ventures logo
RA Capital Management logo
Longwood Fund logo
Bristol Myers Squibb logo
Atlas Venture logo
Arch Venture Partners logo
Alta Partners logo

Be Biopharma is developing engineered B cell medicines to produce therapeutic proteins for treating conditions like Hemophilia B and Hypophosphatasia.

Equity
$82M
10/22/2024
Article
Aktis Oncology logo
Aktis Oncology

Biotechnology

RA Capital Management logo
RTW Investments logo
Janus Henderson Investors logo
T. Rowe Price Associates logo
MRL Ventures Fund logo
Eli Lilly and Company logo
Bristol Myers Squibb logo
Avidity Partners logo

Aktis Oncology is a clinical-stage biotechnology company developing a proprietary radiopharmaceutical pipeline, including Nectin-4-targeted miniprotein radioconjugates, for cancer treatment.

Series B
$175M
09/30/2024
Article

Navigator Medicines develops biologics for targeted immune regulation and restoration, focusing on OX40L-targeted mono- and bispecific antibodies.

Series A
$100M
08/27/2024
Article
AM Batteries logo
AM Batteries

Additive Manufacturing

Toyota Ventures logo
Zeon Ventures logo
TDK Ventures logo
RA Capital Management logo
Porsche Ventures logo
Industry Ventures logo
Foothill Ventures logo
Doral Energy-Tech Ventures logo

AM Batteries specializes in advanced lithium-ion dry-electrode technology for more energy-efficient and environmentally friendly battery manufacturing, aiming to reduce energy consumption, capital expenditures, and carbon footprint in the battery production process.

Series B
$30M
12/04/2023
Article
NTx logo
NTx

Biomanufacturing

RA Capital Management logo
BlueStone Venture Partners logo
Anzu Partners logo

Nature's Toolbox, Inc. (NTx) develops next-generation biomanufacturing platforms for manufacturing mRNA vaccines and protein therapeutics.

Series B
$47.5M
11/16/2023
Article

Forward Therapeutics is a company focused on advancing the development of next-generation small molecule immune therapies.

Series A
$50M
11/08/2023
Article
Aiolos Bio logo
Aiolos Bio

Biopharmaceutical

Sofinnova Investments logo
RA Capital Management logo
Forbion logo
Bain Capital Life Sciences logo
Atlas Venture logo

Aiolos Bio is a clinical-stage biopharmaceutical company focused on respiratory and inflammatory conditions, with a lead drug candidate, AIO-001, that is a potentially best-in-class TSLP antibody dosed every 6 months.

Series A
$245M
10/24/2023
Article
Rampart Bioscience logo
Rampart Bioscience

Biotechnology

OrbiMed logo
Forbion logo
RA Capital Management logo
HealthCap logo

Rampart Bioscience is a biotechnology company developing next-generation biologics using their proprietary DNA-based medicines platform, HALO, with a focus on treating hypophosphatasia.

Series A
$85M
10/24/2023
Article

Ventricle Health is a virtual cardiology care network that offers virtual therapy, remote patient monitoring, and patient education and advocacy, with plans to expand its heart failure management therapeutic model in collaboration with value-based care provider groups and payers.

Seed
$8M
10/19/2023
Article
Commons Clinic logo
Commons Clinic

Healthcare

Time BioVentures logo
RA Capital Management logo
Floating Point logo
Courtside Ventures logo

Commons Clinic is a Los Angeles-based health system specializing in spine, orthopedics, and pain management, offering comprehensive care programs and a network of physicians, care centers, surgical facilities, and a virtual clinic.

Series A
$19.5M
10/10/2023
Article
Adela logo
Adela

Blood Testing

RA Capital Management logo
OrbiMed logo
Labcorp logo
F-Prime Capital logo
Deerfield Management logo
Decheng Capital logo

Adela is a healthcare technology company that specializes in blood testing for early cancer detection and minimal residual disease monitoring using a genome-wide methylome enrichment platform.

Equity
$48M
09/26/2023
Article
Vaxess Technologies logo
Vaxess Technologies

Life Sciences

Ulu Ventures logo
The Engine logo
RA Capital logo
GHIC logo

Vaxess Technologies is a life sciences company that is developing a sustained release patch technology for the stable, refrigeration-free administration of vaccines and therapeutics, with a current focus on mRNA vaccines.

Equity
$9M
09/13/2023
Article
Mariana Oncology logo
Mariana Oncology

Biotechnology

Forbion logo
Deep Track Capital logo
Surveyor Capital logo
RA Capital Management logo
Nextech Invest logo
Eli Lilly and Company logo
Atlas Venture logo
Access Biotechnology logo

Mariana Oncology is a biotechnology company that develops targeted peptide-based radiopharmaceuticals for the treatment of cancer, with a focus on delivering optimized radiation doses to solid tumors.

Series B
$175M
09/07/2023
Article
Nimbus Therapeutics logo
Nimbus Therapeutics

Computational Drug Discovery

SR One logo
GV logo
Atlas Venture logo
SV Health Investors logo
RA Capital Management logo
Pfizer Ventures logo
Bain Capital Life Sciences logo
BVF Partners logo

Nimbus Therapeutics is a clinical-stage company that uses computational chemistry and structure-based drug design to develop novel therapies for immunology, cancer, and metabolic diseases.

Equity
$210M
09/06/2023
Article
Star Therapeutics logo
Star Therapeutics

Biotechnology

Sofinnova Investments logo
Westlake Village BioPartners logo
OrbiMed logo
Redmile Group logo
RA Capital Management logo
Qatar Investment Authority logo
New Leaf Venture Partners logo
NYBC Ventures logo

Star Therapeutics is a biotechnology company that develops first-in-class antibody therapies, primarily for hematology and immunology, and also generates additional biotech companies focused on discovering and advancing novel antibody therapies.

Series C
$90M
09/05/2023
Article

Superluminal Medicines is a generative biology and chemistry company that uses machine learning and big data to advance small molecule drug discovery programs, with a focus on high-value G protein-coupled receptor (GPCR) targets.

Seed
$33M
09/04/2023
Article
Sortera Technologies logo
Sortera Technologies

Material Recycling

T. Rowe Price Associates logo
RA Capital Management-Planetary Health logo
Mitsubishi logo
Macquarie logo
Chrysalix logo
Breakthrough Energy Ventures logo
Assembly Ventures logo

Sortera Technologies is a material sorting company that uses artificial intelligence data analytics to sort pre-production aluminum and end-of-life mixed metals, enabling the use of recycled material in manufacturing, reducing costs and pollution, and increasing availability for domestic manufacturers.

Series C
$30.5M
08/31/2023
Article
ExcepGen logo
ExcepGen

Genetic Medicine

RA Capital Management logo
Gravity Fund logo
Apollo Projects logo

ExcepGen is a genetic medicine startup that develops technology to enhance the effectiveness and tolerability of nucleic acid therapeutics, potentially expanding the reach of DNA-based and RNA-based genetic medicines.

Equity
$4M
08/24/2023
Article